2 news items
Crinetics Presents New Data at ENDO 2024 that Increases Body of Evidence Positioning Once-Daily, Oral Paltusotine as Potential First-Choice Treatment Option for Acromegaly
CRNX
3 Jun 24
was rapid, with the majority of the effect in IGF-1 reductions observed between weeks two and four, and sustained throughout treatment.Among those
Crinetics Pharmaceuticals To Present Advancements From Atumelnant And Paltusotine Development Programs At ENDO 2024 June 1-4, 2024
CRNX
8 May 24
, Massachusetts."This year's Endocrine Society meeting represents a major milestone for Crinetics as we present initial findings from two clinical
- Prev
- 1
- Next